FluoroPharma Medical (FPMI) Stock Price

FluoroPharma Medical Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

FluoroPharma Medical's net margin stands at -11.8%, up from -63.6% several years earlier. The stock trades about 100% above its 52-week low.

FluoroPharma Medical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of FluoroPharma Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how FluoroPharma Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing FluoroPharma Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

FluoroPharma Medical Stock Price History
DateFluoroPharma Medical Price
8/12/20260.00 USD
8/11/20260.00 USD
8/10/20260.00 USD
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/3/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/19/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
8/25/20250.00 USD
8/22/20250.00 USD
8/21/20250.00 USD
8/20/20250.00 USD
8/19/20250.00 USD
8/18/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

FluoroPharma Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2009
0.00 USD
-20,000.00 USD
-20,000.00 USD
Jan 1, 2010
0.00 USD
-890,000.00 USD
-950,000.00 USD
Jan 1, 2011
0.00 USD
-3.27 M USD
-4.24 M USD
Jan 1, 2012
0.00 USD
-4.15 M USD
-4.18 M USD
Jan 1, 2013
0.00 USD
-4.36 M USD
-7.28 M USD
Jan 1, 2014
0.00 USD
-5.17 M USD
-4.69 M USD
Jan 1, 2015
0.00 USD
-3.19 M USD
-3.74 M USD
Jan 1, 2016
0.00 USD
-2.20 M USD
-2.57 M USD

FluoroPharma Medical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 4:58 PM
 
EBITM USD
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2007200820092010201120122013201420152016
––––-3.00-4.00-4.00-5.00-3.00-2.00
––––-4.00-4.00-7.00-4.00-3.00-2.00
––––––75.00-42.86-25.00-33.33
10.5411.0011.0012.7117.7322.6424.3728.6430.0433.56
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales FluoroPharma Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue FluoroPharma Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare FluoroPharma Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares FluoroPharma Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against FluoroPharma Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

FluoroPharma Medical stock margins

The FluoroPharma Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of FluoroPharma Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for FluoroPharma Medical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2009
88.24 %
- %
- %
Jan 1, 2010
88.24 %
- %
- %
Jan 1, 2011
88.24 %
- %
- %
Jan 1, 2012
88.24 %
- %
- %
Jan 1, 2013
88.24 %
- %
- %
Jan 1, 2014
88.24 %
- %
- %
Jan 1, 2015
88.24 %
- %
- %
Jan 1, 2016
88.24 %
- %
- %

FluoroPharma Medical Stock Revenue, EBIT, Earnings per Share

The FluoroPharma Medical earnings per share therefore indicates how much revenue FluoroPharma Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2009
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2010
0.00 USD
-0.07 USD
-0.07 USD
Jan 1, 2011
0.00 USD
-0.18 USD
-0.24 USD
Jan 1, 2012
0.00 USD
-0.18 USD
-0.18 USD
Jan 1, 2013
0.00 USD
-0.18 USD
-0.30 USD
Jan 1, 2014
0.00 USD
-0.18 USD
-0.16 USD
Jan 1, 2015
0.00 USD
-0.11 USD
-0.12 USD
Jan 1, 2016
0.00 USD
-0.07 USD
-0.08 USD

FluoroPharma Medical business model & stock analysis

FluoroPharma Medical Inc is an innovative company from the USA that specializes in molecular imaging. It was founded in 2003 and is based in Boston, Massachusetts. The company's goal is to improve the diagnosis and treatment of cardiovascular and cancer diseases. The business model of FluoroPharma Medical is based on the development of radioactive tracers that are used in conjunction with imaging techniques such as PET (Positron Emission Tomography). These tracers are typically administered in the form of radiopharmaceuticals and allow real-time tracking of metabolic processes in the body of patients. The information obtained is used by doctors to make diagnoses and optimize treatment. FluoroPharma Medical specializes in the development of tracers specifically for cardiovascular and cancer diseases. These include the tracer BFPET (up to 3 hours), which is used for the diagnosis of coronary heart disease, and the tracer CardioPET (up to 3 hours), which is used for the diagnosis of cardiovascular diseases. In addition, the company is working on other tracers that are intended for the diagnosis of various types of cancer, such as prostate cancer, breast cancer, and lung cancer. FluoroPharma Medical is divided into different divisions to better organize its activities. The Research and Development division is responsible for the development of new tracers and conducting clinical studies. The Production division is responsible for the manufacturing and distribution of radiopharmaceuticals. Marketing and distribution are handled by the Sales and Marketing division, which works closely with doctors and hospitals. The products of FluoroPharma Medical are currently still in the development phase and not commercially available. However, the company is working closely with various universities and medical facilities to test its tracers in clinical trials. The aim is to demonstrate the effectiveness and safety of the tracers and obtain approval from the FDA (Food and Drug Administration). FluoroPharma Medical has established itself as a pioneer in the field of molecular imaging and is committed to further improving the diagnosis and treatment of cardiovascular and cancer diseases. With its innovative tracers and focus on clinical practice, the company has the potential to significantly improve the medical care of patients in the future.

FluoroPharma Medical SWOT Analysis

Strengths

FluoroPharma Medical Inc possesses several key strengths that contribute to its competitive advantage in the market. These include:

  • Advanced Technology: FluoroPharma utilizes cutting-edge technology to develop novel molecular imaging agents, providing accurate and precise diagnostic tools for medical professionals.
  • Diverse Product Portfolio: The company offers a wide range of innovative diagnostic imaging agents, catering to various medical needs and enhancing its market presence.
  • Strong Intellectual Property: FluoroPharma holds a robust portfolio of patents and intellectual property rights, safeguarding its research and development efforts and providing a barrier to entry for potential competitors.
  • Strategic Partnerships: The company has established strategic collaborations with leading healthcare organizations, enabling access to resources, expertise, and market opportunities.
  • Experienced Management Team: FluoroPharma is led by a talented and experienced management team with a proven track record in the medical technology industry, fostering innovation and driving growth.

Weaknesses

FluoroPharma Medical Inc faces certain weaknesses that may hinder its performance and market position. These weaknesses include:

  • Financial Dependency: The company may heavily rely on external funding to support its research and development activities, posing a potential risk of limited financial resources.
  • Regulatory Challenges: FluoroPharma operates within a highly regulated industry, and delays or obstacles in obtaining regulatory approvals for its products can impact market entry timelines and competitiveness.
  • Competition: The medical imaging market is highly competitive, with well-established players and constant technological advancements. This poses challenges for FluoroPharma to differentiate and capture market share.

Opportunities

FluoroPharma Medical Inc can leverage several opportunities to enhance its market position and growth prospects. These opportunities include:

  • Increasing Demand for Molecular Imaging: The rising prevalence of chronic diseases and the need for early and accurate diagnosis create a growing market demand for effective molecular imaging agents, which FluoroPharma can capitalize on.
  • Emerging Markets: Expanding into emerging markets presents an opportunity for FluoroPharma to access new customer bases, drive revenue growth, and establish a global presence.
  • Product Pipeline Expansion: Continuously investing in research and development can lead to the development of new and improved diagnostic imaging agents, enabling the company to address unmet medical needs and gain a competitive edge.

Threats

FluoroPharma Medical Inc encounters several threats that may pose challenges to its success and profitability. These threats include:

  • Market Volatility: The medical technology industry is subject to rapid changes, shifting customer preferences, and economic fluctuations, which may impact product demand and financial stability.
  • Regulatory and Legal Risks: Compliance with complex regulations and potential legal disputes can lead to delays, increased costs, and reputational damage.
  • Technological Changes: Advancements in imaging technologies and the emergence of alternative diagnostic methods may render FluoroPharma's products obsolete or less competitive.
  • Price Pressure: Pricing pressures from healthcare providers, insurers, and government healthcare policies can significantly impact the company's profitability and pricing strategies.

FluoroPharma Medical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

FluoroPharma Medical historical P/E ratio, EBIT multiple, and P/S ratio

FluoroPharma Medical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

FluoroPharma Medical shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2009
11.00 M Stocks
Jan 1, 2010
12.71 M Stocks
Jan 1, 2011
17.73 M Stocks
Jan 1, 2012
22.64 M Stocks
Jan 1, 2013
24.37 M Stocks
Jan 1, 2014
28.64 M Stocks
Jan 1, 2015
30.04 M Stocks
Jan 1, 2016
33.56 M Stocks
Price targets and forecasts for FluoroPharma Medical are not yet available.

FluoroPharma Medical Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
11/19/2014-0.05USD-0.00USD-2014 Q3
8/14/2014-0.05USD-0.00USD-2014 Q2

FluoroPharma Medical shareholder structure

% Name
0.00000%
Williams Jones Wealth Management LLC
Williams Jones Wealth Management LLC

FluoroPharma Medical Executives and Management Board

6 members · avg. age 61 · 0 % women

TT

Dr. Thomas Tulip (66)

Chief Executive Officer, Director · since 2015

320,000.00 USD

Management

AE

Mr. Ambrose Egbuonu

President, Treasurer, Company Secretary

–
FI

Mr. Frank Igwealor

Chief Financial Officer, Controller, Director · since 2022

–
RM

Richard Moyer

IR Contact Officer of Cameron Associates, Inc.

–

Board of Directors

WW

Mr. Walter Witoshkin (71)

Independent interim chairman of the board · since 2011

–
WL

Mr. William Lewis (46)

Independent Director

–

Frequently asked questions about FluoroPharma Medical

The business model of FluoroPharma Medical Inc is centered around developing and commercializing molecular imaging pharmaceuticals for use in the field of nuclear medicine. Through its advanced technology platform, the company aims to improve patient diagnosis and treatment. FluoroPharma Medical Inc focuses on developing novel radiopharmaceuticals for positron emission tomography (PET) imaging, which enable non-invasive visualization and quantification of biological processes in the body. By providing innovative diagnostic solutions, the company contributes to enhancing the efficiency and precision of medical procedures, leading to better patient outcomes.

FluoroPharma Medical Inc is primarily active in the pharmaceutical and healthcare industries.

The main competitors of FluoroPharma Medical Inc in the market are Cardinal Health, Bracco Imaging, and GE Healthcare.

FluoroPharma Medical Inc is a specialized molecular imaging company that develops pharmaceuticals to enhance patient care. Founded in 2003, the company focuses on the research and development of innovative diagnostic imaging agents with specific applications in cardiology, oncology, and neurology. FluoroPharma's cutting-edge technologies enable medical professionals to accurately identify and assess various medical conditions and diseases. With a strong commitment to advancing personalized medicine, FluoroPharma Medical Inc utilizes positron emission tomography (PET) imaging to provide precise diagnostic information, aiding in early detection and effective treatment planning. This commitment to groundbreaking molecular imaging solutions makes FluoroPharma Medical Inc a trusted leader in the field.

FluoroPharma Medical Inc has achieved several significant milestones. The company successfully completed a Phase II clinical trial for CardioPET, an imaging agent used to detect cardiac ischemia. Additionally, FluoroPharma received clearance from the U.S. FDA to begin Phase II trials for BFPET, a diagnostic imaging agent for Alzheimer's disease. Furthermore, the company entered into a strategic collaboration with Advanced Accelerator Applications to develop and commercialize cardiovascular imaging agents. These achievements demonstrate FluoroPharma's commitment to advancing innovative imaging technologies for improved patient care.

FluoroPharma Medical Inc is primarily present in the United States.

FluoroPharma Medical Inc represents values of innovation, dedication, and commitment to improving healthcare through cutting-edge molecular imaging agents. With a strong corporate philosophy centered around research and development of novel imaging agents, FluoroPharma Medical Inc aims to provide physicians and patients with advanced diagnostic tools for better disease detection and treatment. By continuously seeking innovative solutions and leveraging its expertise in molecular imaging, FluoroPharma Medical Inc strives to enhance patient care and contribute to the advancement of personalized medicine.

Converted at the current exchange rate, the FluoroPharma Medical share trades at 0.00 EUR (0.00 USD).

FluoroPharma Medical Inc is a company specialized in developing innovative molecular imaging solutions for the diagnosis of cardiovascular diseases and cancer. Its business model aims to develop and distribute these innovative drugs and technologies to medical institutions, research facilities, and pharmaceutical companies worldwide. One of FluoroPharma's core areas is the conception and development of molecular imaging solutions. These solutions allow for the early detection of diseases before they manifest and lead to serious health complications. The company manufactures its imaging solutions in collaboration with leading scientists, clinical researchers, and experts in biomedical imaging. Another core area of FluoroPharma is clinical research and development. The company continuously conducts clinical studies to evaluate the efficacy and safety of its products. It employs highly qualified medical professionals involved in the development and execution of clinical studies. This ensures that FluoroPharma's products meet the highest standards and deliver the best possible results to patients. FluoroPharma has a portfolio of innovative molecular imaging solutions for the diagnosis of cardiovascular diseases and cancer. The company develops and sells both therapeutic and diagnostic imaging solutions. The diagnostic portfolio includes PET imaging solutions such as CardioPET, the earliest PET imaging solution for patients. The company also offers BFPET, an innovative proprietary PET imaging solution for the diagnosis of breast cancer. FluoroPharma also manufactures therapeutic imaging agents used for targeted diagnosis and treatment of diseases. One such imaging agent is AZPET, an innovative PET imaging agent for the diagnosis and treatment of prostate cancer administered in conjunction with targeted therapy. FluoroPharma Medical has achieved broad market presence through partnerships and strategic alliances with research institutions and pharmaceutical companies in the United States and Europe. The company has an experienced and dedicated team of experts in all areas - from research and development to sales strategy. This expertise enables FluoroPharma to be successful in the market and maintain a leading position in the field of molecular imaging solutions. Overall, we can say that FluoroPharma Medical Inc. is an innovative company that offers a wide range of molecular imaging solutions and has a deep understanding of the needs of patients, physicians, and pharmaceuticals. Through collaboration with leading scientists and experts, the company strives to develop sophisticated products and services to improve patients' lives and promote health.

The revenue cannot currently be calculated for FluoroPharma Medical.

The profit cannot currently be calculated for FluoroPharma Medical.

The P/E ratio cannot be calculated for FluoroPharma Medical at the moment.

The P/S cannot be calculated for FluoroPharma Medical currently.

The Eulerpool Quality Score for FluoroPharma Medical is 2/10.

The ISIN of FluoroPharma Medical is US3438701019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of FluoroPharma Medical is FPMI. The ticker symbol is used to trade FluoroPharma Medical shares on the stock exchange.

FluoroPharma Medical paid dividends every year for the past 0 years.

FluoroPharma Medical is assigned to the 'Health' sector.

The dividends of FluoroPharma Medical are distributed in USD.

All fundamentals and in-depth analysis of FluoroPharma Medical

Our stock analysis for FluoroPharma Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FluoroPharma Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

FluoroPharma Medical Stock
FluoroPharma Medical Revenue→
FluoroPharma Medical Stock
FluoroPharma Medical Net Income→
FluoroPharma Medical Stock
FluoroPharma Medical P/E→
FluoroPharma Medical Stock
FluoroPharma Medical P/S→
FluoroPharma Medical Stock
FluoroPharma Medical EBIT→
FluoroPharma Medical Stock
FluoroPharma Medical Dividend→
FluoroPharma Medical Stock
FluoroPharma Medical Directors Dealings→
FluoroPharma Medical Stock
FluoroPharma Medical Stocks→
FluoroPharma Medical Stock
FluoroPharma Medical Market capitalization→
FluoroPharma Medical Stock
FluoroPharma Medical Debt→
FluoroPharma Medical Stock
FluoroPharma Medical Liabilities→
FluoroPharma Medical Stock
FluoroPharma Medical Equity→
FluoroPharma Medical Stock
FluoroPharma Medical AAQS→
FluoroPharma Medical Stock
FluoroPharma Medical Employees→
FluoroPharma Medical Stock
FluoroPharma Medical ROE→
FluoroPharma Medical Stock
FluoroPharma Medical ROA→
FluoroPharma Medical Stock
FluoroPharma Medical ROCE→
FluoroPharma Medical Stock
FluoroPharma Medical News→
FluoroPharma Medical Stock
FluoroPharma Medical Analyst Price Targets→

Health Stocks

Foghorn TherapeuticsFluoguide ASForesee Pharmaceuticals CoFluicellFormosa LaboratoriesFlexion TherapeuticsFormosa PharmaceuticalsFleuryFormyconFlerieForte BiosciencesFisher & Paykel Healthcare CorporationAll Stocks A–Z →